BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.

[2][3][4][5] It was developed by the Israel Institute for Biological Research (IIBR).

[2][6][7] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.

[8][9] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.

You can help Wikipedia by expanding it.This article about COVID-19 vaccines is a stub.